Risk of scleroderma according to the type of immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Risk of scleroderma according to the type of immune checkpoint inhibitors

Published:2020-08 Issue:8 Volume:19 Page:102596
ISSN:1568-9972
Container-title:Autoimmunity Reviews
language:en
Short-container-title:Autoimmunity Reviews

Author:

Terrier Benjamin,Humbert Sébastien,Preta Laure-Hélène,Delage Laure,Razanamahery Jérôme,Laurent-Roussel Sara,Mestiri Raphaële,Beaudeau Lauren,Legendre Paul,Goupil François,Hadjadj Jérôme,Stolzenberg Marie-Claude,Treluyer Jean-Marc,Westeel Virginie,Valnet-Rabier Marie-Blanche,Wislez Marie,Mouthon Luc,Chouchana Laurent

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference18 articles.

1. Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer;Baraibar;Drug Saf,2019

2. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy;Kostine;Rheumatol Oxf Engl,2019

3. Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors;Percik;Autoimmun Rev,2020

4. Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern;Matas-García;Autoimmun Rev,2020

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scleroderma-like Lesions in a Patient Undergoing Combined Pembrolizumab and Routine Chemotherapy: A Case Report and Literature Review;Medicina;2024-07-03

2. Characteristics and management of sclerosing skin diseases during immune checkpoint inhibitor therapy: An evidence-based review;Journal of the American Academy of Dermatology;2024-07

3. De novo Connective Tissue Disorders as Immune-related Adverse Events;Rheumatic Disease Clinics of North America;2024-05

4. Morphoea and Allied Scarring and Sclerosing Inflammatory Dermatoses;Rook's Textbook of Dermatology;2024-03-19

5. Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report;Clinical, Cosmetic and Investigational Dermatology;2024-03